Navigation Links
Possible new approach to treating deadly leukemia in babies
Date:4/13/2011

MAYWOOD, Ill. -- A Loyola University Health System study points to a promising new approach to treating an aggressive and usually fatal leukemia in babies.

The study involved a type of leukemia called mixed lineage leukemia, or MLL. Only 25 to 50 percent of babies diagnosed with MLL leukemia survive the disease.

The study demonstrated how it may be possible to kill cancerous MLL cells by targeting a protein called DOT1. Researchers showed that, without the DOT1 protein, cancerous MLL cells died, said Charles Hemenway, MD, PhD, senior author of the study.

"We are focusing on the unique biology of MLL leukemia," Hemenway said.

The study was presented at the 2011 meeting of the American Association for Cancer Research.

Between 5 and 10 percent of all leukemias are MLL positive. In children older than 1 who have MLL leukemia, the survival rate is about 75 percent. By comparison, the survival rate for most other childhood leukemias is about 90 percent. Adults who have MLL leukemia also have lower survival rates than adults with other types of leukemia.

MLL is a subtype of leukemia caused by a mutation in a gene called MLL. The mutated gene codes for an abnormal MLL protein, which turns a blood cell into a cancer cell. For reasons researchers don't understand, MLL leukemia is more resistant to chemotherapy than other forms of leukemia.

In previous studies, Loyola researchers developed a small molecule, called PFWT, that binds to the MLL protein. This binding effectively disables the MLL protein, leading to the death of the cancer cell. Later this year, Hemenway plans to begin testing PFWT molecules on mice that have MLL leukemia.

The new study points to a second possible way to attack MLL cells, by targeting the DOT1 protein. DOT1 works in conjunction with the MLL protein. The study demonstrated that DOT1 is critical for keeping cancer MLL cancer cells alive.

Researchers cultured MLL cells from mice. From these cells, res
'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Digoxin may be a possible treatment for prostate cancer
2. Freezing Wrinkles a Possible Alternative to Botox
3. Remove childrens catheters as soon as possible to prevent bloodstream infections
4. FDA Panel Examines Possible Links Between Food Dyes, ADHD
5. Researchers find possible clues to tamoxifen resistance in breast cancer patients
6. A possible new target for treatment of multiple sclerosis
7. A safer, more effective morphine may be possible with Indiana University discovery
8. Scientists ID possible biomarker to gauge Alzheimers prognosis, effect of therapies
9. Researchers discover possible biomarker and therapeutic target for melanoma
10. Accurate measurement of radioactive thoron possible at last
11. Nature Reviews Cancer article traces possible role of damaged DNA in tumor development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Benjamin ... Georgia proudly offers the latest non-surgical double-chin eliminator. ... facial plastic surgeon in Atlanta to offer Kybella ... to be injected specifically under the chin, promising to ... , Before Kybella, patients who sought immediate solutions for ...
(Date:5/4/2015)... Morganville, NJ (PRWEB) May 04, 2015 ... that he has been chosen to receive the America’s ... Board. Dr. Champagne’s selection as a top dentist ... his commitment to continuing education and his compassion for ... Board selects professionals who exemplify excellence in their field. ...
(Date:5/4/2015)... For partners who’d like to become parents, ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional lubricants ... Astroglide TTC™ is specially formulated to provide a better ... for Disease Control, an average of one in ... a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... The Accreditation for Cardiovascular ... congenital heart disease (CHD) standards for Pediatric ... Driven by the latest available clinical evidence, ... of interventional procedures in pediatric patients and ... ACE CHD Standards for PCCL Accreditation, like ...
(Date:5/4/2015)... May 04, 2015 Sara Soulati, CEO ... practice management firm in Los Angeles associated with the ... patent-pending status of The Sara Soulati Health For Life ... 2010, is a lifestyle modification and disease prevention program. ... to the U. S. Patents and Trademarks Office and ...
Breaking Medicine News(10 mins):Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... Birner Dental Management,Services, Inc. (Nasdaq: ... announced results for the year ended December ... $2.2 million, or 3.9%, to $59.4,million. Net ... $40.8 million. The,Company,s earnings before interest, taxes, ...
... with dietary restrictions and personal ... ... and created,its own software program that essentially reads the labels for ... online and highlights the ones that meet customers,unique nutritional needs, whether ...
... As the April 15 tax deadline,looms, filers ... term care,insurance, according to LTC Financial Partners LLC, ... *(PHOTO 72dpi: Send2Press.com/mediaboom/07-0807-LTCTruesdell_72dpi.jpg), *(Photo Caption: LTC ... policies can deduct substantial sums," says Cameron,Truesdell, CEO ...
... SAN DIEGO, March 17 The Pharmaceutical,Research and ... with the U.S. Fish and Wildlife Service (USFWS) ... the nation,s fish and,aquatic resources from the improper ... -- will inform people on how to safely ...
... /PRNewswire/ - Organogenesis, Inc., announced,today that Damien ... the company as,vice president of medical affairs., ... Bates combines more than twelve years of ... He has practiced in,orthopedic, dermatologic, vascular, oncologic ...
... Their gentle nature, large size, odd sounds and ... tools and pets for years. But the giant insects ... feces are home to many mold species that could ... handle the bugs, according to a new study. , ...
Cached Medicine News:Health News:Birner Dental Management Services, Inc. Announces 10.0% Adjusted EBITDA Increase for 2007 Versus 2006 2Health News:Birner Dental Management Services, Inc. Announces 10.0% Adjusted EBITDA Increase for 2007 Versus 2006 3Health News:Birner Dental Management Services, Inc. Announces 10.0% Adjusted EBITDA Increase for 2007 Versus 2006 4Health News:Birner Dental Management Services, Inc. Announces 10.0% Adjusted EBITDA Increase for 2007 Versus 2006 5Health News:Birner Dental Management Services, Inc. Announces 10.0% Adjusted EBITDA Increase for 2007 Versus 2006 6Health News:Birner Dental Management Services, Inc. Announces 10.0% Adjusted EBITDA Increase for 2007 Versus 2006 7Health News:Birner Dental Management Services, Inc. Announces 10.0% Adjusted EBITDA Increase for 2007 Versus 2006 8Health News:Peapod Offers First Ever Virtual Nutritionist 2Health News:TAX ALERT: Deductions for Long Term Care Insurance Premiums 2Health News:Medicine Disposal Partnership Will Encourage Public to Flush Less, Crush More 2Health News:Medicine Disposal Partnership Will Encourage Public to Flush Less, Crush More 3Health News:Organogenesis Names Regenerative Medicine Expert Dr. Damien Bates Vice President, Medical Affairs 2Health News:Organogenesis Names Regenerative Medicine Expert Dr. Damien Bates Vice President, Medical Affairs 3Health News:Hissing cockroaches are popular, but they also host potent mold allergens 2
(Date:5/4/2015)... May 4, 2015  NeuroSigma ® , Inc. (NeuroSigma), a ... results of an animal study of its Thin Film Nitinol ... by Mayo Clinic researchers at the 53 rd Annual ... Chicago, Illinois . A copy of the study abstract ... The study at Mayo Clinic was primarily funded through ...
(Date:5/4/2015)... 2015 Dynatronics Corporation (the "Company") (NASDAQ: ... rehabilitation and physical therapy products, announced today that ... approximately $4,000,000 in a private placement financing led ... affiliates (together with its affiliates, "Prettybrook"), a strategic ... The financing will provide Dynatronics with additional capital ...
(Date:5/4/2015)... 2015   Mallinckrodt plc (NYSE: MNK ), ... 13, 2015, at the Bank of America Merrill Lynch 2015 ... Las Vegas, Nev. ... Officer, and Cole Lannum , Senior Vice President of ... in a session scheduled to begin at 3 p.m. Eastern ...
Breaking Medicine Technology:NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting 2NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting 3NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting 4Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 3Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 4Mallinckrodt To Present At Bank Of America Merrill Lynch 2015 Health Care Conference 2
... 04, 2007 /PRNewswire/ -- GlaxoSmithKline today,announced results ... in,advanced or metastatic renal cell carcinoma (RCC), ... trials were presented at the,43rd Annual Meeting ... in Chicago. The results observed in these ...
... Calif., June 04, 2007 /PRNewswire/ -- (SEND2PRESS,NEWSWIRE) -- ... historic landmark in medical oncology and a,definitive benchmark ... first clinical report of its kind, Le Morte ... the International Journal of,Oncology, Vol.30, pp. 1297-1307 -- ...
Cached Medicine Technology:GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 2GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 3GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 4GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 5GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 6GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 7News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 2News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 3
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This is a single-action instrument that features a spring handle....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: